Revenue from the large Spanish order, the Ortega order, is not included in this quarter. Varian's interoperability with RayCare is driven by customer demand and Varian's policy. RaySearch has 85% market share in proton therapy and 12% in photon therapy.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay